Analytical Data
-
Gene name
LEAP2
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q969E1
-
Expression Region
Ser23~Gln76
-
Molecular Weight
39kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LEAP2 (liver-expressed antimicrobial peptide 2) is an intriguing protein that has garnered attention due to its potential roles in metabolic regulation and immune response. Initially identified as an antimicrobial peptide, LEAP2 is mainly expressed in the liver and has been implicated in the regulation of energy metabolism, particularly in the context of obesity and type 2 diabetes. Researchers have discovered that LEAP2 interacts with the ghrelin receptor, influencing appetite and energy balance. Given the rising prevalence of metabolic disorders worldwide, understanding the mechanisms behind LEAP2's function could provide valuable insights for developing new therapeutic strategies. Recent studies have explored LEAP2's structural characteristics, its regulatory effects on hypothalamic signaling, and its overall impact on glucose homeostasis. As research continues, LEAP2 is emerging as a potential biomarker for metabolic diseases and a target for innovative treatments aimed at restoring metabolic health. The ongoing investigation into LEAP2's molecular pathways reflects a broader interest in the interplay between the immune system and metabolic regulation, highlighting its significance in both basic and translational research.
